Catalent (CTLT.US) shares gain over 11% after publishing preliminary results for the first quarter of the fiscal year 2023/2024 and providing forecasts for the entire year. The company's stock price is rising despite a record loss recorded in the ended period.
Financial Summary
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile app-
Net revenue of $982 million, a decrease of 3.9% year-over-year.
- Biologics net revenue: $447 million, a 15% decrease year-over-year, above the estimated $426.9 million.
- Net revenue from pharmaceuticals and consumer health: increased by 7.2% year-over-year, to $535 million.
-
Net loss of $715 million, including non-cash write-downs of the company's value amounting to $700 million.
-
Adjusted EBITDA of $115 million, a decrease of 38% year-over-year.
Forecasts for the entire fiscal year:
- Net revenue: $4.3 - $4.5 billion.
- Adjusted EBITDA: $680 - $760 million.
- Net profit: $113 - $175 million.
In their commentary, the management emphasized Catalent's strategic achievements, including the strategic review initiated in August and changes in the board after a settlement with Elliott Investment Management. Despite these challenges, Catalent expects that the majority of its pre-filled syringe production capacities until 2026 will be fully booked in the short period, due to high demand for new weight-loss drugs from Danish drugmaker Novo Nordisk's Wegovy.
Catalent (CTLT.US) shares are gaining over 11% in today's trading. The increases are driven by optimistic forecasts and positive management sentiment. However, the company's recent problems have pushed its stock price to multi-year lows this year. The current rebound is still a fraction of the share price at the peak of the pandemic bull market, at $140 per share. The current increase is capped by levels of $46 and $51, and breaking through these levels could indicate a breakout from consolidation. Source: xStation 5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
